HT-29 cells were obtained from ATCC and were derived from a 44 year old female patient with grade II adenocarcinoma and selected on the basis of the stage II enrichment of Fn in patients with CRC (Extended Data Fig. 1a). The gene discussed is FN1; the disease is adenocarcinoma.